Why is Ionis Pharmaceuticals stock at a 52-week low on Monday?
Ionis Pharmaceuticals Inc. IONS stock is trading at a 52-week low after the company lowered Tryngolza (olezarsen) 2026 ...
Model output · Signal date 2026-11-09
Ionis Pharmaceuticals Inc (IONS) Stock Forecast Nov. 9, 2026
Analysis updated on Nov. 9, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Rating · 90D
Unlock rating and forecasts
90-day forecast
Sign up free to reveal
30-day forecast
Alpha
Rank in coverage
of 4224 stocks scored
Rank correlation · 90D
20.0%
Spearman, 358 dates
Market Cap
$6.55B
mid-cap · #48 of 60 peers
Summary
Ionis Pharmaceuticals Inc (IONS) stock forecast summary
Our AI scores Ionis Pharmaceuticals Inc every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Ionis Pharmaceuticals Inc is a mid-cap company with a market capitalization of $6.55B. It ranks number 48 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast.
For IONS, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 20.0%, measured on 358 forecast dates between 2022-08-22 and 2026-08-11 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 10.0%, measured on 401 forecast dates between 2022-08-22 and 2026-10-09. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +3.1%, buy ≥ +1.6%, sell < -0.3%, strong sell < -1.7% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-11-09 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, IONS included.
Price
IONS price chart and AI forecast
Cross-section · 2026-11-09
How IONS ranks among 4224 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fundamentals · 2026-06-30
Ionis Pharmaceuticals Inc (IONS) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Pharmaceutical Preparations peers listed below that report each metric.
Valuation & Market
| Metric | IONS | Rank |
|---|---|---|
| Market Cap | $6.55B | 48/60 |
| P/B Ratio | 14.90x | 9/42 |
| EPS | $-3.77 | – |
| Book Value/Share | $2.65 | – |
| Revenue/Share | $1.60 | – |
| FCF/Share | $-3.37 | – |
Profitability & Margins
| Metric | IONS | Rank |
|---|---|---|
| ROE | -128.5% | 33/38 |
| ROA | -18.9% | 32/42 |
| ROIC | -22.2% | 33/44 |
| Gross Margin | 94.0% | 5/36 |
| Operating Margin | -224.0% | 35/38 |
| Net Margin | -213.0% | 32/35 |
| EBT Margin | -211.8% | 43/46 |
| Tax Rate | -0.6% | – |
Financial Health
| Metric | IONS | Rank |
|---|---|---|
| Current Ratio | 7.89x | 13/58 |
| Quick Ratio | 7.73x | 1/43 |
| D/E Ratio | 5.81x | 3/47 |
| Financial Leverage | 6.81x | 3/47 |
| Interest Coverage | -22.1x | 26/33 |
| Working Capital | $2.18B | 17/58 |
Cash Flow
| Metric | IONS | Rank |
|---|---|---|
| Operating Cash Flow | -$496M | 55/59 |
| Free Cash Flow | -$561M | 47/50 |
| Capital Spending | -$64M | 27/50 |
| FCF/Sales | -211.4% | 40/42 |
| CapEx/Sales | 24.3% | 3/42 |
Operational Efficiency
| Metric | IONS | Rank |
|---|---|---|
| Asset Turnover | 0.09x | 37/39 |
| Inventory Turnover | 0.3x | 34/35 |
| Fixed Assets Turnover | 1.7x | 37/41 |
| Days Inventory | 1158 days | 2/35 |
| Payables Period | 1087 days | 1/24 |
Income Statement
| Metric | IONS | Rank |
|---|---|---|
| Total Revenue | $265M | 43/46 |
| Operating Income | -$594M | 47/50 |
| Net Income | -$565M | 39/46 |
| SG&A Expense | $528M | 33/40 |
| Cost of Goods Sold | $16M | 35/37 |
Dividend & Shareholder Information
| Metric | IONS | Rank |
|---|---|---|
| Shares Outstanding | 166M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $2.49B | 83.2% of assets |
| Cash & Short-term Investments | $350M | 11.7% of assets |
| Inventory | $51M | 1.7% of assets |
| Total Liabilities | $2.55B | 85.3% of assets |
| Short-term Debt | $268M | 8.9% of assets |
Quarterly Financial Reports
IONS quarterly financials and insider trading
Industry Peers · Pharmaceutical Preparations
Ionis Pharmaceuticals Inc (IONS) industry peers
Companies classified under the same SEC industry code as Ionis Pharmaceuticals Inc (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| IONS Ionis Pharmaceuticals Inc | $6.55B | |
| LLY Eli Lilly & Co | $1.27T | |
| JNJ Johnson & Johnson | $664.95B | |
| ABBV Abbvie Inc. | $518.30B | |
| MRK Merck & Co., Inc. | $362.01B | |
| NVS Novartis Ag | $310.17B | |
| AZN Astrazeneca Plc | $293.55B | |
| ABT Abbott Laboratories | $192.16B | |
| NVO Novo Nordisk A S | $179.14B | |
| PFE Pfizer Inc | $167.51B | |
| VRTX Vertex Pharmaceuticals Inc / Ma | $138.67B | |
| BMY Bristol Myers Squibb Co | $127.02B | |
| SNY Sanofi | $115.97B | |
| GSK Gsk Plc | $101.54B | |
| REGN Regeneron Pharmaceuticals, Inc. | $93.11B | |
| TAK Takeda Pharmaceutical Co Ltd | $65.66B | |
| TEVA Teva Pharmaceutical Industries Ltd | $49.65B | |
| ONC Beone Medicines Ltd. | $46.26B | |
| GMAB Genmab A/S | $34.50B | |
| ZTS Zoetis Inc. | $32.81B | |
| RPRX Royalty Pharma Plc | $28.82B | |
| ROIV Roivant Sciences Ltd. | $28.08B | |
| INSM Insmed Inc | $25.10B | |
| UTHR United Therapeutics Corp | $24.11B | |
| VTRS Viatris Inc | $22.87B | |
| ALNY Alnylam Pharmaceuticals, Inc. | $20.98B | |
| ASND Ascendis Pharma A/S | $17.07B | |
| JAZZ Jazz Pharmaceuticals Plc | $15.24B | |
| BBIO Bridgebio Pharma, Inc. | $15.18B | |
| ELAN Elanco Animal Health Inc | $13.41B | |
| SMMT Summit Therapeutics Inc. | $13.03B | |
| RDY Dr Reddys Laboratories Ltd | $12.44B | |
| BMRN Biomarin Pharmaceutical Inc | $11.07B | |
| TGTX Tg Therapeutics, Inc. | $9.49B | |
| MDGL Madrigal Pharmaceuticals, Inc. | $9.23B | |
| SYRE Spyre Therapeutics, Inc. | $9.16B | |
| PTGX Protagonist Therapeutics, Inc | $8.54B | |
| CORT Corcept Therapeutics Inc | $8.11B | |
| PRAX Praxis Precision Medicines, Inc. | $7.75B | |
| ALKS Alkermes Plc. | $7.75B | |
| RYTM Rhythm Pharmaceuticals, Inc. | $7.73B | |
| CYTK Cytokinetics Inc | $7.67B | |
| KNSA Kiniksa Pharmaceuticals International, Plc | $7.37B | |
| AXSM Axsome Therapeutics, Inc. | $7.02B | |
| ARWR Arrowhead Pharmaceuticals, Inc. | $6.96B | |
| ABVX Abivax S.A. | $6.83B | |
| ORKA Oruka Therapeutics, Inc. | $6.81B | |
| AMRX Amneal Pharmaceuticals, Inc. | $6.80B | |
| BLTE Belite Bio, Inc | $6.20B | |
| LGND Ligand Pharmaceuticals Inc | $6.12B | |
| MIRM Mirum Pharmaceuticals, Inc. | $6.09B | |
| COGT Cogent Biosciences, Inc. | $5.82B | |
| MANE Veradermics, Inc | $5.80B | |
| SUPN Supernus Pharmaceuticals, Inc. | $5.56B | |
| PTCT Ptc Therapeutics, Inc. | $5.47B | |
| ERAS Erasca, Inc. | $5.04B | |
| DNTH Dianthus Therapeutics, Inc. /De/ | $5.03B | |
| EWTX Edgewise Therapeutics, Inc. | $4.89B | |
| TVTX Travere Therapeutics, Inc. | $4.44B | |
| LEGN Legend Biotech Corp | $4.33B |
Where IONS sits on the market map
Life Sciences · Pharmaceutical Preparations
News
Ionis Pharmaceuticals Inc (IONS) stock news
Ionis Pharmaceuticals Reports 55% Rise in Q3 Revenue to $243 Million, Cuts TRYNGOLZA Sales Guidance
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) reported third-quarter 2026 revenue of $243 million, compared with $157 million a ...
Ionis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026
Ionis Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2026. For the third quarter, the company reported revenue was USD 243 million compared ...
FAQ
Ionis Pharmaceuticals Inc (IONS) stock forecast FAQ
What is the Ionis Pharmaceuticals Inc (IONS) stock forecast?
Our AI scores Ionis Pharmaceuticals Inc every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
How accurate are Ionis Pharmaceuticals Inc stock predictions?
For IONS, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 20.0%, measured on 358 forecast dates between 2022-08-22 and 2026-08-11 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 10.0%, measured on 401 forecast dates between 2022-08-22 and 2026-10-09. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Ionis Pharmaceuticals Inc forecasts updated?
Ionis Pharmaceuticals Inc forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 9, 2026.
Which companies are Ionis Pharmaceuticals Inc's industry peers?
60 issuers in our coverage, IONS included, share the SEC industry code Pharmaceutical Preparations. The largest are: Eli Lilly & Co (LLY), Johnson & Johnson (JNJ), Abbvie Inc. (ABBV), Merck & Co., Inc. (MRK), Novartis Ag (NVS), Astrazeneca Plc (AZN).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.